Search results
AstraZeneca Buy rating, stock target reiterated on consistent presence By Investing.com
Investing.com· 1 day agoThe company's trials include AVANZAR, evaluating Dato-DXd plus Imfinzi for first-line treatment of...
Former lab workers deemed 'high risk' now eligible for annual lung cancer screenings
Santa Fe New Mexican· 23 hours agoFormer Los Alamos National Laboratory and Sandia National Laboratories employees who are deemed “high risk” will be eligible for a new early lung cancer ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 13 hours agoToday, the American Lung Association is celebrating 120 years of championing lung health by highlighting ways the organization has improved public health ...
National Cancer Survivors Day is a celebration of life
Rolling Out· 3 days agoJune 2 marks a significant occasion for many individuals and families across the globe—it's National...
Six cancer treatment breakthroughs pushing us closer to a cure
The Telegraph via Yahoo News· 7 days agoIt is now being trialled in people for whom standard treatments, such as chemotherapy, have not...
Former lab workers deemed 'high risk' now eligible for annual lung cancer screenings
The Santa Fe New Mexican via Yahoo News· 23 hours agoJun. 5—Former Los Alamos National Laboratory and Sandia National Laboratories employees who are deemed "high risk" will be eligible for a new early lung cancer< ...
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Benzinga via Yahoo Finance· 2 days agoOn Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed...
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
CNBC· 3 days agoModerna and Merck released more positive three-year data Monday on their experimental vaccine, given...
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...
Benzinga via Yahoo Finance· 3 days agoMonday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of...
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer...
The Parsons Sun· 6 days agoResults from the new analysis show the RYBREVANT® combination consistently and significantly improved progression-free survival (PFS) compared to osimertinib in patients with ...